- The i/Blue Imaging System’s(TM) development is the first to harness the power of white light and blue light visualization techniques with the added capability of displaying multiple images simultaneously which will help surgeons perform more accurate tumor resections
- Imagin Medical’s innovative system is currently in the manufacturing phase with Lighthouse Imaging with product completion slated for 2022
- With its patented technology, the company is positioned to stake a claim on a $400 million segment of the $46 billion global endoscopy market
Advancements in the way that cancer is diagnosed and treated continue to be made. On the forefront of new technological innovation for visualizing cancer is Imagin Medical (CSE: IME) (OTCQB: IMEXF) i/Blue(TM) Imaging System, a technology designed to combine the advantages of traditional white light with blue light imaging to provide unparalleled visualization for removal of bladder cancer.
Bladder cancer is the sixth most prevalent cancer found in the United States and has one of the highest recurrence rates. The American Cancer Society estimates there will be 83,730 new cases in 2021 and 17,200 deaths. Men are four times more likely to end up with the disease than women, and it is the eighth most common cause of death in this gender group American Cancer Society
The most common procedure used to detect bladder cancer is called a cystoscopy, a procedure that allows doctors to examine the lining of the bladder by inserting a hollow tube (cystoscope) equipped with a lens into the bladder through the urethra. The cystoscopy allows medical professionals to examine the bladder and the urethra to diagnose, monitor, or treat various conditions, including bladder cancer.
For decades, cystoscopies have been using white light for visualization. This method is still standard for more than 90% of the market, even though it cannot accurately detect cancer growths if they do not protrude past the bladder wall. White light is almost impossible to define clear margins between flat tumors and non-affected bladder tissue.
First introduced in 2010, the blue light cystoscopy (“BLC”) has addressed the limitations imposed by the white light technology. With the use of an FDA-approved contrast agent, the cancerous bladder cells fluoresce in the blue light, providing significantly improved visualization of additional tumors and their margins during cancer removal. However, the current standard for BLC requires surgeons to switch their field of view from white light to blue light for resection purposes. Even with the blue light being more effective for resection, the white light is needed for the surgeon to orient their position within the bladder in real time.
Imagin Medical, a Boston-based surgical imaging company focused on visualizing bladder cancer during minimally invasive surgeries, has set out to address the limitations of both white light and blue light procedures. Using the same FDA-approved contrast, Imagin’s innovative i/Blue technology design will display real-time white and blue light images on the screen simultaneously. This advancement will eliminate the need to switch back and forth between the images and enable more accurate tumor resection and possibly lower recurrence rates.
Additionally, the i/Blue System’s DualView Camera Head was developed to adapt to most endoscopes on the market, allowing hospitals to use the scopes they already have, providing a significant cost savings.
As of March 15, 2021, Imagin Medical is funding its efforts with $2.165 million raised toward its convertible note offering. The company has advanced to the commercial manufacturing stage with Maine-based, FDA registered and ISO 13485:2016 certified Lighthouse Imaging as the contracted system manufacturer, and is scheduled to complete the manufacturing phase in 2022.
With its patented technology, Imagin Medical is positioned to leverage growth opportunities in both the bladder cancer and other minimally invasive procedures. .The endoscopy market is valued at $46 billion, of which Imagin is positing itself to target $400 million (https://ibn.fm/pwNXs). The global bladder cancer market was valued at $3.43 billion in 2018 and is expected to grow at a CAGR of 4.03% to reach a projected value of $4.71 billion by 2026 (https://ibn.fm/h0pts).
For more information, visit the company’s website at www.ImaginMedical.com.
NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
